(MENAFN- GlobeNewsWire - Nasdaq) -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% ...
Dec 12, 2025, 12:09 AM IST Sri Lotus Developers - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Nov 27, 2025, 5:14 PM IST Sri Lotus Developers - Announcement under ...
Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback